203 related articles for article (PubMed ID: 10543929)
1. Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
Eur Heart J; 1999 Nov; 20(22):1657-66. PubMed ID: 10543929
[TBL] [Abstract][Full Text] [Related]
2. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
Eur Heart J; 1997 Sep; 18(9):1416-25. PubMed ID: 9458447
[TBL] [Abstract][Full Text] [Related]
3. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
Linder R; Oldgren J; Egberg N; Grip L; Larson G; Siegbahn A; Wallentin L
Eur Heart J; 1999 Apr; 20(7):506-18. PubMed ID: 10365287
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
Klootwijk P; Lenderink T; Meij S; Boersma H; Melkert R; Umans VA; Stibbe J; Müller EJ; Poortermans KJ; Deckers JW; Simoons ML
Eur Heart J; 1999 Aug; 20(15):1101-11. PubMed ID: 10413640
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
6. Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment.
Andersen K; Dellborg M; Emanuelsson H; Grip L; Swedberg K
Coron Artery Dis; 1996 Sep; 7(9):673-81. PubMed ID: 8950498
[TBL] [Abstract][Full Text] [Related]
7. Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
Oldgren J; Siegbahn A; Grip L; Linder R; Thygesen K; Wallentin L
Thromb Haemost; 2004 Feb; 91(2):381-7. PubMed ID: 14961168
[TBL] [Abstract][Full Text] [Related]
8. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Direct Thrombin Inhibitor Trialists' Collaborative Group
Lancet; 2002 Jan; 359(9303):294-302. PubMed ID: 11830196
[TBL] [Abstract][Full Text] [Related]
9. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
10. Coagulation activity and clinical outcome in unstable coronary artery disease.
Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):1059-64. PubMed ID: 11397720
[TBL] [Abstract][Full Text] [Related]
11. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential.
Becker RC; Spencer FA; Li Y; Ball SP; Ma Y; Hurley T; Hebert J
J Am Coll Cardiol; 1999 Oct; 34(4):1020-7. PubMed ID: 10520784
[TBL] [Abstract][Full Text] [Related]
12. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
Andersen K; Dellborg M
Am J Cardiol; 1998 Apr; 81(8):939-44. PubMed ID: 9576150
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
14. Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.
Oldgren J; Wallentin L; Grip L; Linder R; Nørgaard BL; Siegbahn A
Eur Heart J; 2003 Jan; 24(1):86-93. PubMed ID: 12559940
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
PRIME CARE Study Investigators Group
Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
[TBL] [Abstract][Full Text] [Related]
16. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
17. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
18. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
19. Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia.
Nørgaard BL; Andersen K; Dellborg M; Abrahamsson P; Ravkilde J; Thygesen K
J Am Coll Cardiol; 1999 May; 33(6):1519-27. PubMed ID: 10334417
[TBL] [Abstract][Full Text] [Related]
20. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
Bounameaux H; Ehringer H; Hulting J; Rasche H; Rapold HJ; Zultak M
Thromb Haemost; 1997 Sep; 78(3):997-1002. PubMed ID: 9308743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
